Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 1/20 | 0.37 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.32 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7322217 | 1.00 | MAP3K7 (0.37) | MAP3K7TAB1NR4A2IP6K1IP6K2 | |
| SCHEMBL2632247 | 0.80 | MAPT (0.41) | MAP3K7TAB1APP | |
| SCHEMBL3011424 | 0.80 | APP (0.43) | APP | |
| Cis-Urocanic Acid SCHEMBL19031717 | 0.78 | KDM4E (0.43) | MAP3K7TAB1APP | |
| Cis-Urocanic Acid SCHEMBL1755678 | 0.78 | KDM4E (0.43) | MAP3K7TAB1APP | |
| Cis-Urocanic Acid SCHEMBL1311341 | 0.78 | KDM4E (0.43) | MAP3K7TAB1APP | |
| Cis-Urocanic Acid SCHEMBL15417 | 0.78 | KDM4E (0.43) | MAP3K7TAB1APP | |
| Cis-Urocanic Acid SCHEMBL15418 | 0.78 | KDM4E (0.43) | MAP3K7TAB1APP | |
| SCHEMBL15474115 | 0.77 | — | — | |
| Cis-Urocanic Acid SCHEMBL7715147 | 0.77 | KDM4E (0.42) | MAP3K7TAB1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH IP EE B.V. (NL) | 2010-08-05 | — | — | US | disclosed |
| EP-0242973-B1 | INDOLE DERIVATIVES, METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1991-07-17 | — | — | EP | disclosed |
| US-4808581-A | ANXIOLYTIC, ANTIEMETIC, TREATMENT OF PSYCHOLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 1989-02-28 | — | — | US | disclosed |
| EP-0242973-A1 | Indole derivatives, method for their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | UTS2R, UACA, HCAR1 | MAP3K7 3557/4885TAB1 2315/4885NR4A2 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.